Bionano Genomics to Present at the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Bionano Genomics (BNGO) has announced that Erik Holmlin, PhD, its CEO, will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 2:30 pm ET. The event is tailored for BTIG clients. Bionano specializes in optical genome mapping solutions and offers N_xClinical™, a leading genomic data software. Their mission is to enhance genome visibility through innovative solutions and diagnostic services, including applications in clinical research and autism spectrum disorder diagnostics.

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr^® system and provider of N_xClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Erik Holmlin, PhD, Bionano’s president and chief executive officer, is scheduled to participate in a fireside chat on Wednesday, February 16th, 2022 at 2:30 pm ET. BTIG hosted events are intended for prospective and existing BTIG clients. To listen to the live event, please contact your BTIG representative with interest.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com

Media Relations:
Michael Sullivan
Seismic
+1 (503) 799-7520
michael@teamseismic.com

FAQ

What is the date and time of Bionano Genomics' presentation at the BTIG Conference?

Erik Holmlin will present on February 16, 2022, at 2:30 pm ET.

Who will represent Bionano Genomics at the BTIG MedTech Conference?

Erik Holmlin, PhD, CEO of Bionano Genomics, will represent the company.

What is the purpose of the BTIG conference where Bionano Genomics is presenting?

The BTIG conference is intended for prospective and existing BTIG clients in the MedTech and Life Science sectors.

What kind of solutions does Bionano Genomics provide?

Bionano Genomics offers optical genome mapping solutions and genomic data visualization software.

How can I access the live event for Bionano Genomics' presentation?

To listen to the live event, contact your BTIG representative.